[Observation of 212 cases of typhoid fever treated with FQNS]

To treat 212 cases of typhoid fever with Seven kinds of fluoroquinolones (FQNS) and to evaluate their clinical efficacy, bacterial susceptibility and adverse drug reaction (ADR).

All the cases were hospitalized and uniantibiotic treated in which NFX group (n = 43) was compared with CP group (n = 28).

204/212 (96.23%) cases were positively cultured. All except 9 (S. paratyphi) were S. typhi. Of the 212 clinically isolated strains, 194(91.51%) were susceptible to FQNS with K-B assay. The MIC except 1 (6.25 mg/L) were all < or = 4 mg/L. The results of MIC detection with 20 strains of clinically isolated bacteria in 1994 and 1995 showed that FQNS were apparently superior to other antityphoid fever antibiotics as chloramphenicol and cefoperazone. When FQNS were used the overall clinical cure rate was 98.11%, the bacterial clear rate was 99.51%, and the rate of ADR was 11.3%. No difference was found between the NFX group and CP group in defervescent days and the cure rates and bacterial carrier state in recovery. The rate of recurrence and ADR in the NFX group was lower than that in the CP group. With the improvement of pharmacokinetics, new FQNS can be administered once or twice a day, and the therapy course shortened from 14 to 7 days. It is considered that FQNS are currently the first choice of antibacterials in treating typhoid fever.